

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



(51) International Patent Classification <sup>5</sup> : A61K 31/00, 39/35, 45/00 A61K 49/00	A1	(11) International Publication Number: <b>WO 93/07863</b>
		(43) International Publication Date: 29 April 1993 (29.04.93)
(21) International Application Number: PCT/US92/08775 (22) International Filing Date: 14 October 1992 (14.10.92) (30) Priority data: 776,624 15 October 1991 (15.10.91) US (71)(72) Applicant and Inventor: MULLARKEY, Michael, F. [US/US]; 1422 Eighth Avenue West, Seattle, WA 98119 (US). (74) Agent: WESEMAN, James, C.; Gray, Cary, Ames & Frye, 401 B Street, Suite 1700, San Diego, CA 92101 (US). (81) Designated States: AU, CA, JF, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).		Published <i>With international search report.</i>
		<b>BEST AVAILABLE COPY</b>
(54) Title: METHODS AND COMPOSITIONS FOR TREATING ALLERGIC REACTIONS		
(57) Abstract  Methods and compositions for treating allergic reactions, including cutaneous, ocular, nasal and bronchial allergic disease, are disclosed. Interleukin-1 and Tumor Necrosis Factor receptors, and analogues thereof, are employed which bind the respective effector competitively and thereby suppress allergic reactions.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroon	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TG	Togo
DE	Germany	ML	Mali	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

-1-

DescriptionMethods and Compositions for Treating Allergic ReactionsTechnical Field

5 The present invention relates to methods and compositions for treating allergic reactions, and, more particularly, for treating bronchial asthma, rhinitis, rhinoconjunctivitis, conjunctivitis, and dermatitis.

Background of the Invention

10 An allergic reaction is any abnormal or altered reaction to an antigen (or "allergen"). Typically such a reaction is characterized by hypersensitivity of the body to specific substances, whether protein, lipid or carbohydrate in nature. Allergic reactions may be local, e.g. contact dermatitis, or systemic, e.g. anaphylaxis.

15 Among allergic diseases, bronchial asthma is one of the most significant. In most urban hospitals, it is the leading cause of admission of children. Current medical practice accepts asthma in afflicted individuals to be an unavoidable, incurable illness. While suppression of  
20 symptoms is achieved to a degree sufficient to avoid death, urgent medical visits, disturbed sleep, and days lost from work are typically unavoidable.

The disease is generally associated with dyspnea, wheezing, and cough, as well as reversible airway  
25 obstruction and airway hyperreactivity to nonspecific stimuli. These responses have been observed in two phases, early and late (Lemanske, Jr., R.F. and M.A. Kaliner, In: Allergy, Principles & Practice (3rd Ed.) pp. 224-246 (1988). See also Kaliner, M.A., *Hosp. Prac.*  
30 22:73 (1987); Larsen, G., *Hosp. Prac.* 23:113 (1987)).

Inhalation of allergens by sensitized subjects typically results in an early phase response characterized by bronchoconstriction within 10 minutes of inhalation, reaching a maximum within 1 to 2 hours. In

-2-

some subjects, the airway narrowing recurs after 3 to 4 hours (i.e. a late phase response), reaching a maximum during the next few hours (O'Byrne, P.M. *et al.*, *Am. Rev. Respir. Dis.* 136:740 (1987)). This late phase reaction is thought to be due to the cellular phase of inflammation (Hargreave, F.E. *et al.*, *Eur. J. Respir. Dis.* 69(Suppl 147):16 (1986); O'Byrne, P.M., *Chest* 90:575 (1986); Dolovich, J. *et al.*, *J. Allergy Clin. Immunol.* 83(Suppl):521 (1987)).

No complete, long-lasting remissions of asthma have been described in response to any existing therapeutic strategies. For example, systemically administered glucocorticosteroids are potent antiasthmatics; however, the symptoms of the disease are only temporarily suppressed and this is at the cost of well-known side effects, including osteoporosis, weight gain, hypertension, and diabetes (Barnes, P.J., *New Eng. J. Med.* 321:1517 (1989)). Inhaled steroid therapy also has complications (See Toogood, J.H., *J. Allergy Clin. Immunol.* 83(Suppl):528 (1987)). Low-dose methotrexate has been offered as a substitute to steroids, particularly for patients for whom the side-effects of steroids are the most devastating (Mullarkey, M.F., *New Eng. J. Med.* 318:603 (1988)). However, methotrexate, while frequently substituting for toxic doses of corticosteroids, has significant inherent toxicity. Furthermore, it does not eliminate the need for periodic corticosteroids.

There is a great need for new approaches to treatment of allergic disease. Specifically, there is a need for therapy that produces long-lasting anti-inflammatory effect without harm to the patient.

-3-

Disclosure of the Invention

The present invention relates to methods and compositions for treating allergic reactions, including cutaneous, ocular, nasal, gastrointestinal and bronchial allergic disease.

In accordance with the present invention, at least one member selected from the group consisting of Interleukin-1 (IL-1) receptors, Tumor Necrosis Factor (TNF) receptors, and receptor analogues thereof which bind the respective effector, is selectively employed to treat allergic reactions. The present treatment is expected to have many of the beneficial effects of corticosteroids -- however, without the toxicity associated with these agents.

One aspect of the present invention contemplates using soluble IL-1 receptors to treat inflammation in tissues. In certain embodiments, this method comprises contacting inflamed tissue with a therapeutic preparation comprising soluble IL-1 receptors. In other embodiments, the inflamed tissue is skin and the inflammation is contact dermatitis, urticaria, angioedema or atopic dermatitis. In additional embodiments, the ocular tissue is inflamed and the inflammation is allergic conjunctivitis. In still other embodiments, the nasal tissue is inflamed and the inflammation is rhinitis. In yet additional embodiments, the lung tissue is inflamed and the inflammation is bronchial asthma.

The present invention also contemplates using such receptors or receptor analogues in combination with other pharmaceuticals (e.g. corticosteroids) to treat inflammation in tissues. In certain embodiments, this method comprises contacting inflamed tissue with a therapeutic preparation comprising a mixture of such receptors and pharmaceuticals such as corticosteroids (e.g. prednisone) and antihistamines.

-4-

In other embodiments, the present method comprises contacting inflamed tissue with a therapeutic preparation comprising, in combination, both TNF and IL-1 receptors.

5 The present invention also contemplates using an allergic assay to screen for anti-allergic drugs. In one embodiment, the present invention comprises using a skin test to measure anti-inflammatory characteristics of pharmaceuticals.

10 Therapeutic compositions containing such receptors and analogues thereof are also provided in accordance with the present invention.

#### Brief Description of the Drawing

15 The single figure schematically depicts exogenous receptors (shaded) competitively binding effectors (linked beads) to inhibit the binding of the effectors to endogenous receptors in a cell membrane.

-5-

Detailed Description of the Invention

The present invention relates to methods and compositions for treating allergic reactions, and particularly, without limitation, bronchial asthma, rhinoconjunctivitis, conjunctivitis, dermatitis, urticaria, chronic bronchitis, allergic and non-allergic rhinitis and inflammatory lung disease. In accordance with the present invention, a therapeutic composition comprising at least one member selected from the group consisting of Interleukin-1 (IL-1) receptors, Tumor Necrosis Factor (TNF) receptors, and receptor analogues thereof which bind the respective effector, is applied exogenously to inflamed tissues. The present invention contemplates the use of IL-1 receptors, TNF receptors, analogues thereof which bind the respective effector or combinations and mixtures thereof, in a therapeutic preparation.

It is presently considered desirable that the receptors and their analogues will be soluble in a medium appropriate to the particular application contemplated. As used herein, the term "soluble" shall mean sufficient solubility in the selected medium so that the receptors are capable of migrating to a position wherein they are able to bind with the endogenous effector, unless a contrary meaning is clear from the context in which the term is used.

As used herein, the term "effector" shall mean IL-1 and/or TNF interchangeably, unless a contrary meaning is clear from the context in which the term is used.

As used herein, the term "substantial" shall mean an amount sufficient to cause a detectable therapeutic effect, unless a contrary meaning is clear from the context in which the term is used.

-6-

IL-1 and IL-1 receptors

Interleukin-1 $\alpha$  (IL-1 $\alpha$ ) and Interleukin-1 $\beta$  (IL-1 $\beta$ ) are distantly related polypeptide hormones which play a central role in the regulation of immune and inflammatory responses (See Cerretti *et al.*, U.S. Patent Nos. 4,894,333 and 4,879,374, each hereby incorporated by reference). These two proteins were originally both classified as IL-1, based on a shared lymphocyte activation factor activity and a common major cellular source, i.e. activated macrophages. As information has accumulated from studies using purified natural and recombinant IL-1 molecules, it has become clear that IL-1 $\alpha$  and IL-1 $\beta$  each mediate most, if not all, of the wide range of activities previously ascribed to IL-1. The basis for this nearly identical spectrum of biological activities is thought to be that a single class of plasma membrane IL-1 receptors bind both IL-1 $\alpha$  and IL-1 $\beta$ .

The existence of IL-1 plasma membrane receptors is now well-established. While original structural characterizations of the IL-1 receptor were limited to estimates of the molecular weight of this protein by gel filtration, by SDS-PAGE analysis of covalent complexes formed by chemical cross-linking between the receptor and <sup>125</sup>I-IL-1 molecules, and by immunoprecipitation of labeled surface proteins, one of the receptors has now been cloned and expressed in high yield (See Dower, U.S. Patent No. 4,968,607 assigned to Immunex Corporation, hereby incorporated by reference).

TNF and TNF receptors

Tumor Necrosis Factor (TNF- $\alpha$ ) plays a critical role in the development of acute pulmonary failure and injury. When released into the lung, TNF- $\alpha$  has devastating effects, causing rapid and diffuse tissue injury. This is presumably a direct result of its known effects on



-7-

endothelial cells and granulocytes, as well as its induction of other mediators such as IL-1, prostaglandins, and platelet-activating factor. When TNF- $\alpha$  is induced in the lungs of animals by the inhalation of endotoxin, airways develop a pattern of reactivity that is characteristic of bronchial asthma (See Pauwels, R.A. et al., Am. Rev. Resp. Dis. 141:540 (March 1990)).

The use of blocking antibodies has made it possible to ablate the toxic action of TNF- $\alpha$ . Baboons can be protected from a lethal intravenous doses of E. coli organisms by prior administration of monoclonal anti-TNF- $\alpha$ (ab') fragments (See Tracey, N.J., Nature 330:662 (1987)).

Tumor Necrosis Factor- $\alpha$  and TNF- $\beta$  receptors have been isolated and DNA sequences encoding these secretory proteins have been described (See Smith et al., European Patent Application No. 90309875.4 (Publication No. 0418014A1), assigned to Immunex Corporation, hereby incorporated by reference; See also U.S. Patent Application Ser. Nos. 07/405,370, 07/421,417, and 07/523,635, hereby incorporated by reference).

#### Receptor Analogues

The present invention also contemplates the use of receptor analogues, and in particular IL-1 receptor analogues and TNF receptor analogues, as therapeutic agents. IL-1 receptor analogues are those compounds which act in an analogous manner to competitively bind IL-1 and inhibit the binding of IL-1 to endogenous IL-1 receptors. An example of such an analogue is described in European Patent Application No. 343684, hereby incorporated by reference. In that case, the analogue is a polypeptide inhibitor of Interleukin-1. See also U.S. Patent Application Nos. 07/199,915, 07/238,171,

-8-

07/238,713, 07/248,521, and 07/266,531, each hereby incorporated by reference.

Such analogues which fall within the scope of the invention also include truncated molecules, and molecules  
5 with amino acid additions, substitutions and deletions, wherein regions of the receptor molecule not required for effector binding have been altered or deleted.

The analogues of the present invention share as a common feature the ability to competitively bind the  
10 respective effector to a degree sufficient to display a therapeutic effect when used in the practice of the present invention.

#### The Use of IL-1 Receptors and TNF Receptors

Since the IL-1 proteins are primary regulators of  
15 immunological responses, some investigation has been made into the ability of IL-1 receptors to modify immune responses. For example, Fanslow, W.C. *et al.*, *Science* 248:739 (1990) describes the regulation of alloreactivity *in vivo* by a soluble form of the IL-1 receptor. They  
20 found that systemic administration of the receptor prolonged the survival of heart allografts. In addition, Jacobs, C.A. *et al.*, *J. Immunol.* 146:2983 (1991) describes the use of soluble IL-1 receptor to suppress experimental autoimmune encephalomyelitis. These  
25 researchers found that interperitoneal administration of the receptor reduced the severity of the disease.

In contrast to these previous uses of IL-1 receptor, the present invention contemplates the topical use of IL-1 receptor on inflamed tissue. In particular, the  
30 present invention contemplates the topical, as well as the parenteral use of IL-1 receptor to suppress the early and late phase response in allergic reactions, including the late phase response in bronchial asthma.

-9-

Similarly, the present invention contemplates the topical use of TNF receptor on inflamed tissue. In particular, the present invention contemplates the topical, as well as the parenteral use of soluble TNF  
5 receptor to suppress the early and late phase response in allergic reactions, including the late phase response in bronchial asthma.

While the benefits conveyed by treatment according to the present invention are not dependent on a precise  
10 understanding of the mechanism(s) by which the subject receptors achieve a therapeutic result, it is believed that the suppression of allergic responses is accomplished by competitive binding of the exogenously supplied, receptors and/or analogues thereof to the  
15 respective effector, thereby inhibiting the binding of the effector to endogenous receptors on the tissue, as schematically portrayed in the Figure.

In the manner thus illustrated, IL-1 receptors or TNF receptors supplied exogenously are expected to  
20 competitively bind to IL-1 or TNF, respectively, thereby inhibiting the binding of the effector to the endogenous receptor.

In practicing the method of the present invention, the therapeutic preparation will be administered to a  
25 host in need of anti-allergic treatment at a therapeutically effective dosage level. The lowest effective dosage levels can be determined routinely by initiating treatment at higher dosage levels and reducing the dosage level until relief from allergic reaction is  
30 no longer obtained. Generally, therapeutic dosage levels will range from about 0.01-100 $\mu$ g/kg of host body weight.

-10-

Therapeutic Preparations and Combinations

The present invention contemplates using therapeutic compositions of the present receptors or analogues thereof to treat inflammation in tissues, as well as  
5 therapeutic preparations comprising, in combination, both TNF and IL-1 receptors. Furthermore, the present invention also contemplates using IL-1 receptors, TNF receptors, receptor analogues, and combinations thereof in combination with corticosteroids or other  
10 antiinflammatory drugs or molecules in a therapeutic preparation to treat inflammation in tissues.

Where combinations are contemplated, it is not intended that the present invention be limited by the particular nature of the combination. The present  
15 invention contemplates combinations as simple mixtures as well as chemical hybrids. One example of the latter is where the receptor is covalently linked to a pharmaceutical such as a corticosteroid, or where two receptor types are joined. For example, covalent binding  
20 of the distinct chemical moieties can be accomplished by any one of many commercially available cross-linking compounds. Further examples of such chemical hybrids include combinations of the receptors together or with other biologically active or inert molecules prepared to  
25 utilize the effects of IL-1 receptor and/or TNF receptor. Such hybrid or fusion molecules can be constructed using the techniques of genetic engineering. Similar such molecules have been created by several methods utilizing promoter genes (See, e.g., Feng, G. et al., *Science*  
30 241:1501 (1988)).

It is not intended that the present invention be limited by the particular nature of the therapeutic preparation. For example, such compositions can be provided together with physiologically tolerable liquid,  
35 gel or solid carriers, diluents, adjuvants and excipients.

-11-

These therapeutic preparations can be administered to mammals for veterinary use, such as with domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage  
5 required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts.

Such compositions are typically prepared as sprays (e.g. intranasal aerosols) for topical use. However,  
10 they may also be prepared either as liquid solutions or suspensions, or in solid forms including respirable and nonrespirable dry powders. Oral formulations (e.g. for gastrointestinal inflammation) usually include such normally employed additives such as binders, fillers,  
15 carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions,  
20 suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain 1%-95% of active ingredient, preferably 2%-70%.

The compositions are also prepared as injectables, either as liquid solutions or suspensions; solid forms  
25 suitable for solution in, or suspension in, liquid prior to injection may also be prepared.

The receptors of the present invention are often mixed with diluents or excipients which are physiologically tolerable and compatible. Suitable  
30 diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof. In addition, if desired the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH  
35 buffering agents.

-12-

Additional formulations which are suitable for other modes of administration, such as topical administration, include salves, tinctures, creams, lotions, and, in some cases, suppositories. For salves and creams, traditional binders, carriers and excipients may include, for example, polyalkylene glycols or triglycerides.

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

#### EXPERIMENTAL

In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar);  $\mu$ M (micromolar); N (Normal); mol (moles); mmol (millimoles);  $\mu$ mol (micromoles); nmol (nanomoles); kg (kilograms); gm (grams); mg (milligrams);  $\mu$ g (micrograms); L (liters); ml (milliliters);  $\mu$ l (microliters); cm (centimeters); mm (millimeters);  $\mu$ m (micrometers); nm (nanometers); and °C (degrees Centigrade).

#### Example 1

This example describes the use of soluble IL-1 receptor to reduce the cutaneous allergic reactions following the intradermal administration of antigen.

Early and late phase responses have been observed following bronchial challenge with such antigens as ragweed pollen and house dust. Importantly, these responses in lung tissue correspond in time to the early and late phase reactions in skin following intradermal challenge with similar antigens (See Dolovich, J. and D.C. Little, *J. Allergy Clin. Immunol.* 49:43 (1972); See also Solley, G.O. et al., *J. Clin. Invest.* 58:408 (1976)). Skin reactivity to allergen, especially the Late Phase Reaction (LPR) skin test is believed to be

-13-

predictive of events occurring in the lungs of asthmatics.

The LPR skin test is performed by interadermally injecting subjects on the forearm with test solution. The test solution contains the challenging antigen. Controls receive test solution without challenging antigen. The injection site is thereafter examined at intervals up to 96 hours. The diameters of the reactions are measured in two perpendicular directions and the characteristics are noted at different times.

Most subjects exhibit a dual reaction, the LPR beginning at the 4 hour point and reaching a peak at the 8-12 hour point. The LPR gradually subsides over a 24 hour period. At the peak, the injection site is characterized by erythema, warmth, edema, pruritus and/or tenderness. The LPR is more extensive in area and produces greater discomfort than the early phase reaction.

In this example, the LPR skin test is performed on individuals; all have previously had a dual response (early and late) to intradermal challenge with antigen as described above. Dust mite antigen is used (*D. pteronyssinus*; Allergy Laboratories of Ohio; 30,000AU/ml). The soluble IL-1 receptor (Immunex Corp.; Seattle, Washington) stock concentration is 10mg/ml. Eight test solutions are prepared for intradermal injections (0.01ml each) using TB syringes and disposable needles. Four intradermal test sites are used on each forearm.

Two test solutions are controls. Histamine phosphate (Allermed Labs; 1.8mg/ml) is used as a positive control, and saline is used as a negative control. The six remaining test solutions all contain dust mite antigen; three contain IL-1 receptor (final concentration 1.65mg/ml) while the other three contain saline. Three

-14-

concentrations of the antigen are evaluated (final concentrations: 1:500,000, 1:200,000, and 1:100,000).

5 The area of the wheal reaction is marked on the skin with a ball-point pen. Clear adhesive tape is then applied to the marked skin. The tape with the pen markings is removed from the skin and taped on paper with 0.1mm squares. The wheal reactions are then calculated by counting the squares within the pen-marked area.

10 At twenty minutes post injection, the control allergen injection (i.e. containing no receptor) at the lowest concentration produces a wheal more than half the area of the histamine reaction after subtracting the response to the diluent control. By contrast, the wheal produced by injections containing IL-1 receptor are  
15 reduced.

At two hours the early phase subsides. The LPR peaks between eight and 13 hours. At its peak, the control allergen injection (i.e. containing no receptor) at the lowest concentration produces a wheal larger than  
20 that observed at 20 minutes, while the wheal produced by injections containing IL-1 receptor are reduced by at least 50 percent.

The results of this example, while specific for IL-1 receptors, nonetheless shows the general applicability of  
25 using an allergic assay to screen for anti-allergic drugs. Indeed, this skin test is appropriate to measure anti-inflammatory characteristics of any pharmaceutical.

If desired, a pathologic assessment can be made of the allergic reaction in addition to measuring the wheal  
30 visually in the simple skin test. At eight hours a punch biopsy can be taken at one or more of the allergen sites on each forearm. Standard hematoxylin and eosin staining can be performed on formalin-fixed, paraffin-embedded sections. The assessment is made according to the  
35 pattern and type of cellular infiltration at the biopsy sites. The sites can be graded on a 0 to 3 scale (none,



-15-

mild, moderate or severe on the basis of presence and extent of i) perivascular infiltrate, ii) interstitial infiltrate and edema, and iii) leukocytoclasia.

Particular note can be taken with regard to the presence of lymphocytes, eosinophils, macrophages, granulocytes and any other cellular element which is increased in number or unique to normal skin.

#### Example 2

This example describes the use of soluble IL-1 receptor to reduce the LPR following conjunctival provocation with antigen.

Ocular involvement is common in allergic conditions. It can be the result of systemic allergic symptoms or, indeed, the main focus of allergic disease.

With respect to specific ocular allergies, allergic rhinoconjunctivitis, atopic keratoconjunctivitis, vernal conjunctivitis, giant papillary conjunctivitis, and contact allergy have been identified as the primary types. The most commonly seen form of ocular allergy is the red itchy eyes that accompany allergic rhinitis during the allergy season.

Usually ocular symptoms are overshadowed by nasal or respiratory symptoms. However, in some cases the ocular symptoms predominate. Patients typically complain of red, swollen, itchy eyes, and scant mucous discharge. Itching is an important symptom for ocular allergy since most patients with allergy have itching, and very few other ocular conditions are associated with itching. Other common ocular reactions include giant papillary conjunctivitis (associated with contact lenses) and contact allergy (caused frequently by soaps, shampoos, and eye makeup).

To study ocular involvement, allergists have developed protocols to measure conjunctival allergic response. Conjunctival provocation tests in allergic

-16-

individuals have been used to confirm the diagnosis of allergy, study the physiologic changes accompanying the allergic reaction, sample the cells and mediators of the allergic response, and evaluate anti-inflammatory therapy.

The conjunctival provocation test (CPT) is a good way of determining the presence or absence of allergy. This is particularly true when a skin test is negative or equivocal. Moreover, the CPT has been found to be safe; the cornea is not affected, and patient discomfort is mild and transient.

Eosinophilia is normally absent in conjunctival scrapings taken from nonallergic individuals. The presence of conjunctival eosinophilia is considered to be a diagnostic indicator of allergic conjunctivitis, and the severity of the disease appears to correlate with the level of major basic protein in tears.

The tear fluid can also be sampled to evaluate the mediators of ocular inflammation. Tear IgE levels have been measured in allergic patients and in general, there is a correlation between the tear and serum IgE levels. This correlation exists when serum IgE is greater than 100IU/ml and tear IgE is greater than 4IU/ml.

To evaluate the severity of the response, the eye can be examined with a strong flashlight, or if available, a slit-lamp microscope. The allergic conjunctive appears inflamed and edematous. Rather than intense redness and prominence of blood vessels, the conjunctiva has a pinkish or milky appearance.

In the present example, inhibition of the ocular symptoms in the LPR is examined; the presence of inflammatory cells in the tear film is correlated with the occurrence of ocular symptoms in the LPR time period.

Ten ryegrass-sensitive patients with hay fever conjunctivitis and ten nonallergic subjects without ocular disease are challenged by weekly topical

-17-

administration of ryegrass allergen for 4 weeks with 10 $\mu$ l of four different allergen doses (10,000, 32,000, 100,000, and 320,000BU/ml of ryegrass allergen) (Pharmalgen, Pharmacia Diagnostics AB, Uppsala, Sweden).

5 Albumin diluent (Pharmacia), is used to dilute the allergen. Five of the patients and five of the nonallergic subjects are given allergen premixed with IL-1 receptor. The other five patients and subjects are given allergen without IL-1 receptor. Importantly, the  
10 allergic patients and control subjects have no clinical symptoms before ocular provocation.

The CPT involves introducing allergen to the lower conjunctival fornix of one eye by applying 10 $\mu$ l of different dilutions of ryegrass in albumin prepared at  
15 the time of testing. The concentration used were 10,000, 32,000, 100,000, and 320,000BU/ml. The other eye was used as a control; at the same time the control eye received 10 $\mu$ l of albumin.

The challenge solution is administered to the  
20 contralateral eye in both patients and control subjects. Clinical conjunctival evaluation with tear-fluid cytology is assessed in both eyes before administration of allergen or buffer 20 minutes, one hour, and six hours after challenge. In both the allergic patients and  
25 control subjects, the following ocular symptoms, both subjective and objective, are evaluated by a physician: hyperemia, edema, tearing, and itching. Each symptom is scored from 0 to 4+ and graded as follows: 0 - absent; 1+ - mild; 2+ - moderate; 3+ - severe; and 4+ - very  
30 severe. The sum of all scores (maximal clinical score, 16) obtained from each item represented the intensity of the clinical reaction at each time point.

A microcapillary tube (Sigma Chemical Co., St. Louis, Mo.) is used to collect 2 $\mu$ l of tears from the  
35 inner canthus without touching the ocular surface. Such collection of tears is a noninvasive technique which

-18-

allows repeated sampling without conjunctival trauma. Tears are spread on a glass slide, air-dried, and stained with Wright-Gemsa (Diff-Quick, Baxter Healthcare Corp., Gibbstown, N.J.). All identifiable cells on each slide  
5 are counted at original magnification x1000 using light microscopy. Five types of cells are scored: epithelial cells, neutrophils, eosinophils, lymphocytes, and monocytes. All participants are first examined prior to provocation to assure that there is no significant  
10 difference in the baseline levels of inflammatory cells in the tear fluid of allergic patients compared with levels of the control subjects.

Following provocation, all allergic subjects receiving allergen without IL-1 receptor exhibit evidence  
15 of an immediate hypersensitivity ocular reaction with all allergen doses; allergic subjects receiving allergen together with IL-1 receptor, exhibit a significantly reduced response. The conjunctival response in allergen-challenged (no receptor) eyes of the allergic  
20 patients is also statistically significant compared with the albumin diluent-treated eyes. A significant number of neutrophils are detected in eyes challenged with 320,000BU/ml of ryegrass allergen (no receptor) compared with the those receiving this dose together with IL-1  
25 receptor.

The highest allergen dose causes the recruitment of a significant number of eosinophils and lymphocytes to the tear fluid 6 hours after provocation (i.e. in late phase) in those eyes challenged with allergen without  
30 receptor. This increase in eosinophils in the tear fluid is not seen in allergic patients receiving allergen with receptor.

-19-

Example 3

This example describes the use of soluble IL-1 receptor to reduce the LPR in nasal tissue following inhalation of antigen.

5           Patients with allergic rhinitis often have immediate symptoms after antigen challenge (the early phase response), followed several hours later by a recurrence of symptoms (the late-phase response). This example involves a controlled study of asymptomatic subjects in  
10           the pollen-free winter months.

          Sixteen patients with seasonal allergic rhinitis due to grass or ragweed pollens are selected. All subjects have a positive intradermal skin test to 10PNU (protein nitrogen units) or less of antigen extract, and all have  
15           previously had a dual response (early and late) to nasal challenge with antigen.

          Ragweed and mixed-grass pollen extracts (timothy, orchard, June and meadow grass in a ratio of 3:2:3:2) are purchased from Greer Laboratories (Lenoir, N.C.);  
20           lactated Ringer's solution and oxymetazoline hydrochloride (Afrin, Schering, Kenilworth, N.J.) are purchased from the hospital pharmacy.

          At the time of the challenge, oxymetazoline hydrochloride is sprayed into the nose (two sprays per  
25           nostril) of all patients to prevent mucosal congestion, which would interfere with the collection of nasal secretions. It has been shown previously that this dose of oxymetazoline does not affect histamine release during the early reaction to antigen.

30           Eight of the sixteen patients receive four prechallenge nasal lavages with IL-1 receptor diluted in buffer; the remaining ten receive lavages with buffer only. Thereafter, challenges with 1000PNU of antigen are undertaken.

35           The patients maintain a symptom score sheet during the challenge procedure. In addition to the number of

-20-

sneezes, a six-point scale from 0 to 5 (with 0 equal to no symptoms and 5 equal to severe symptoms) is used to assess nasal secretion, blockage, and itching. The degree of blockage is, of course, underestimated on those score sheets because of the pretreatment with oxymetazoline hydrochloride. The presence or absence of symptoms correlates with the presence or absence of mediators during the late reaction.

From a comparison of those patients receiving prechallenge treatment with IL-1 receptor and those receiving only buffer, it is clear that pretreatment with IL-1 receptor inhibits both the symptoms and the release of histamine and other inflammatory mediators during not only the late and rechallenge reactions to nasal challenge with antigen but also the early response.

#### Example 4

This example describes the use of soluble IL-1 receptor to reduce the late phase reaction (LPR) in lung tissue following inhalation of allergen.

Airway hyperactivity can be induced or worsened by antigen inhalation, exposure to some irritating chemicals, and by respiratory tract infections. The degree of reactivity is directly correlated with the number of mast cells and eosinophils detected by lavage.

In this example, twenty patients with documented allergic bronchial asthma participate. Allergen inhalation is performed by inhaling dust mite extract (see Example 1, above) at 15 minute intervals using a Wiesbadnener Doppelspray (8L/min air flow, nebulizer output approximately 0.2ml/min). Ten patients received the allergen premixed with IL-1 receptor; the other ten patients received the allergen alone.

Bronchoalveolar lavage performed 6 to 48 hours after inhalation of allergen alone shows increased numbers of eosinophils, mast cells, and desquamated epithelial

-21-

cells. Eosinophil granule major basic protein levels are markedly elevated in the lavage fluid of these asthmatic patients. Peripheral blood eosinophil counts decrease during late phase responses to antigen challenge at the  
5 time eosinophil levels in the pulmonary tissues increases, presumably because of margination and emigration in the lungs.

Bronchoalveolar lavage after inhalation of allergen with IL-1 receptor shows suppression of eosinophil  
10 emigration in the lungs. The histologic data is consistent with the concept that activation of mast cells, infiltration of the tissues by eosinophils and other inflammatory cells, and tissue damage as well as dysfunction induced by inhalation of allergen is markedly  
15 suppressed by the presence of IL-1 receptor.

Thus it has been shown that the present invention provides beneficial methods and compositions for treating allergic reactions, including, without limitation, bronchial asthma, rhinoconjunctivitis, conjunctivitis,  
20 dermatitis, urticaria, chronic bronchitis, allergic and non-allergic rhinitis and inflammatory lung disease.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application  
25 were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be  
30 apparent to those of ordinary skill in the art in light of the teaching of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

-22-

Claims:

5           1.    A method for treating allergic responses comprising contacting inflamed tissue with a preparation comprising at least one member selected from the group consisting of IL-1 receptors, TNF receptors, and receptor analogues thereof which are capable of binding either IL-1 or TNF.

10           2.    The method of claim 1, wherein a substantial portion of the receptors or analogues contained in the preparation are soluble.

          3.    The method of claim 1, wherein said preparation comprises a mixture of IL-1 receptors and TNF receptors.

15           4.    The method of claim 3, wherein at least a portion of said TNF receptors are covalently bound to said IL-1 receptors.

          5.    The method of claim 3, wherein at least a portion of said receptor analogues are hybrid fusion molecules comprising a TNF receptor moiety and an IL-1 receptor moiety.

20           6.    The method of claim 1, wherein the preparation further comprises a therapeutically effective amount of at least one corticosteroid.

25           7.    The method of claim 5, wherein at least a portion of said corticosteroids are covalently bound to said IL-1 receptors.

          8.    The method of claim 1, wherein the tissue to be treated is selected from the group consisting of nasal tissue, ocular tissue, lung tissue, and skin.



-23-

9. A method for testing pharmaceuticals for anti-allergic properties, comprising:

- a) providing a test solution comprising at least one challenging allergen;
- 5 b) providing a pharmaceutical to be tested;
- c) adding said pharmaceutical to said test solution to make a test mixture;
- d) injecting one or more individuals interdermally with said test mixture; and
- 10 e) examining the injection site at intervals after said injecting to determine the extent of an allergic reaction.

10. The method of claim 9, wherein said individuals have previously displayed a dual allergic response (early and late) to intradermal challenge with said allergen.

11. The method of claim 9, wherein said examining step comprises measuring the area of the wheal reaction on the skin of the individuals.

12. A therapeutic composition for treating allergic responses comprising at least one member selected from the group consisting of IL-1 receptors, TNF receptors, and receptor analogues thereof which are capable of binding either IL-1 or TNF, together with a pharmaceutically acceptable carrier adapted for topical or parenteral application to a host in need of such treatment.

13. The therapeutic composition of claim 12, wherein a substantial portion of the receptors or analogues contained in the preparation are soluble.

-24-

14. The therapeutic composition of claim 12, wherein said preparation comprises a mixture of IL-1 receptors and TNF receptors.


5 15. The therapeutic composition of claim 14, wherein at least a portion of said TNF receptors are covalently bound to said IL-1 receptors.

10 16. The therapeutic composition of claim 14, wherein at least a portion of said receptor analogues are hybrid fusion molecules comprising a TNF receptor moiety and an IL-1 receptor moiety.

17. The therapeutic composition of claim 12, wherein the preparation further comprises a therapeutically effective amount of at least one corticosteroid.

15 18. The therapeutic composition of claim 17, wherein at least a portion of said corticosteroids are covalently bound to said IL-1 receptors.

1/1



SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/08775

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :A61K 31/00, 39/35, 45/00, 49/00

US CL :424/9, 85.2, 88; 514/1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9, 85.2, 88; 514/1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE

search terms: allergy, anti-allergic, interleukin-1, IL-1, TNF

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	THE JOURNAL OF IMMUNOLOGY, Volume 146 No. 9, issued 01 May 1991, C.A. Jacobs, et al, "Experimental Autoimmune Encephalomyelitis is Exacerbated by IL-1 $\alpha$ and Suppressed by Soluble IL-1 Receptor", pages 2983-2989, especially pages 2983, 2984, and 2987.	<u>1, 2, 12, 13</u> 1-8, 12-18
Y	SCIENCE, Volume 248, issued 11 May 1990, W.C. Fanslow, et al, "Regulation of Alloractivity in Vivo by a soluble Form of the Interleukin-1 Receptor", pages 739-742, especially page 741.	1-8, 12-18
Y	THE NEW ENGLAND JOURNAL OF MEDICINE, Volume 321, No. 22, issued 30 November 1989, P.J. Barnes, "A New Approach to the Treatment of Asthma", pages 1517-1525, see entire document.	1-8, 12-18
Y	AMERICAN REVIEW OF RESPIRATORY DISEASES, Volume 141, issued 1990, J. Kelley, "Cytokines of the Lung", pages 765-788, especially page 781.	1-8, 12-18

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

05 December 1992

Date of mailing of the international search report

08 JAN 1993

 Name and mailing address of the ISA/  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

NANCY PARSONS

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/08775

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	CLINICAL ALLERGY, Volume 15, issued 1985, R. Gronneberg, et al, "Effect of disodium cromoglycate on anti-IgE induced early and late skin response in humans", pages 167-171, especially pages 167, 168.	<u>9, 11</u> 10
Y	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Volume 79, No. 5, issued May 1987, D.W. Cockcroft, et al, "Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine", pages 734-740, especially pages 734, 735, 739.	10

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**